These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36218067)

  • 21. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
    Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
    Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of Novel Androgen Receptor Ligands by Structure-based Virtual Screening and Bioassays.
    Zhou W; Duan M; Fu W; Pang J; Tang Q; Sun H; Xu L; Chang S; Li D; Hou T
    Genomics Proteomics Bioinformatics; 2018 Dec; 16(6):416-427. PubMed ID: 30639122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In silico and in vitro assessment of androgen receptor antagonists.
    Serçinoğlu O; Bereketoglu C; Olsson PE; Pradhan A
    Comput Biol Chem; 2021 Jun; 92():107490. PubMed ID: 33932781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plant-derived 3,3'-Diindolylmethane is a strong androgen antagonist in human prostate cancer cells.
    Le HT; Schaldach CM; Firestone GL; Bjeldanes LF
    J Biol Chem; 2003 Jun; 278(23):21136-45. PubMed ID: 12665522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone.
    Sack JS; Kish KF; Wang C; Attar RM; Kiefer SE; An Y; Wu GY; Scheffler JE; Salvati ME; Krystek SR; Weinmann R; Einspahr HM
    Proc Natl Acad Sci U S A; 2001 Apr; 98(9):4904-9. PubMed ID: 11320241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sertad1 promotes prostate cancer progression through binding androgen receptor ligand binding domain.
    Hu B; Hu H; Yin M; Sun Z; Chen X; Li Y; Sun Z; Liu C; Li L; Qiu Y
    Int J Cancer; 2019 Feb; 144(3):558-568. PubMed ID: 30230528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of Prostate Cancer.
    Fancher AT; Hua Y; Camarco DP; Close DA; Strock CJ; Johnston PA
    Assay Drug Dev Technol; 2018; 16(6):297-319. PubMed ID: 30109944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of treatment with androgen receptor ligands on microRNA expression of prostate cancer cells.
    Segal CV; Koufaris C; Powell C; Gooderham NJ
    Toxicology; 2015 Jul; 333():45-52. PubMed ID: 25846647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A-ring-fused pyrazoles of dihydrotestosterone targeting prostate cancer cells via the downregulation of the androgen receptor.
    Peřina M; Kiss MA; Mótyán G; Szczyrbová E; Eliáš M; Študent V; Kurfürstová D; Kovalová M; Mada L; Bouchal J; Frank É; Jorda R
    Eur J Med Chem; 2023 Mar; 249():115086. PubMed ID: 36682291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetic and thermodynamic characterization of dihydrotestosterone-induced conformational perturbations in androgen receptor ligand-binding domain.
    Jasuja R; Ulloor J; Yengo CM; Choong K; Istomin AY; Livesay DR; Jacobs DJ; Swerdloff RS; Miksovská J; Larsen RW; Bhasin S
    Mol Endocrinol; 2009 Aug; 23(8):1231-41. PubMed ID: 19443608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure of the homodimeric androgen receptor ligand-binding domain.
    Nadal M; Prekovic S; Gallastegui N; Helsen C; Abella M; Zielinska K; Gay M; Vilaseca M; Taulès M; Houtsmuller AB; van Royen ME; Claessens F; Fuentes-Prior P; Estébanez-Perpiñá E
    Nat Commun; 2017 Feb; 8():14388. PubMed ID: 28165461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M; Huang Y; Ratnam M
    Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High Content Screening Using New U2OS Reporter Cell Models Identifies Harmol Hydrochloride as a Selective and Competitive Antagonist of the Androgen Receptor.
    Dellal H; Boulahtouf A; Alaterre E; Cuenant A; Grimaldi M; Bourguet W; Gongora C; Balaguer P; Pourquier P
    Cells; 2020 Jun; 9(6):. PubMed ID: 32560058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamic communication between androgen and coactivator: mutually induced conformational perturbations in androgen receptor ligand-binding domain.
    Xu X; Yang W; Wang X; Li Y; Wang Y; Ai C
    Proteins; 2011 Apr; 79(4):1154-71. PubMed ID: 21322031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of prostate cancer cell lines for androgen receptor-mediated reporter gene assays.
    Kim HJ; Park YI; Dong MS
    Toxicol In Vitro; 2006 Oct; 20(7):1159-67. PubMed ID: 16621434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, Synthesis and Evaluation of Novel Substituted (5-methyl-1H-pyrazol-3-yl)- 1,3,4-oxadiazole as Potent Androgen Receptor Antagonist.
    Andavar S; Vaithilingam M; Selvaraj D; Kumaran AA; Devanathan K
    Anticancer Agents Med Chem; 2020; 20(1):84-93. PubMed ID: 31755396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiandrogenic mechanisms of pesticides in human LNCaP prostate and H295R adrenocortical carcinoma cells.
    Robitaille CN; Rivest P; Sanderson JT
    Toxicol Sci; 2015 Jan; 143(1):126-35. PubMed ID: 25324206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer.
    Singh P; Hallur G; Anchoori RK; Bakare O; Kageyama Y; Khan SR; Isaacs JT
    Prostate; 2008 Oct; 68(14):1570-81. PubMed ID: 18668523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Androgen receptor-mediated repression of novel target genes.
    Prescott J; Jariwala U; Jia L; Cogan JP; Barski A; Pregizer S; Shen HC; Arasheben A; Neilson JJ; Frenkel B; Coetzee GA
    Prostate; 2007 Sep; 67(13):1371-83. PubMed ID: 17624924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.